A 'Sci-Fi' Cancer Therapy Fights Brain Tumors, Study Finds | NBC Bay Area
National & International News
The day’s top national and international news

A 'Sci-Fi' Cancer Therapy Fights Brain Tumors, Study Finds

It supposedly works by creating low intensity, alternating electric fields that disrupt cell division, which makes the cells die, but it theoretically mostly harms the disease and not the patient

    processing...

    NEWSLETTERS

    A 'Sci-Fi' Cancer Therapy Fights Brain Tumors, Study Finds
    AP
    In this March 29, 2017 photo, Joyce Endresen wears an Optune therapy device for brain cancer, as she speaks on a phone at work in Aurora, Ill. She was diagnosed in December 2014 with Glioblastoma. She had two surgeries to remove the tumor as well as radiation and chemotherapy, but is now trying the new therapy that requires her to wear the electrodes on her head as much as possible. They create low intensity electric fields that disrupt cell reproduction, which makes the cells die.

    It sounds like science fiction, but a cap-like device that makes electric fields to fight cancer improved survival for the first time in more than a decade for people with deadly brain tumors, final results of a large study suggest.

    Many doctors are skeptical of the therapy, called tumor treating fields, and it's not a cure. It's also ultra-expensive — $21,000 a month.

    But in the study, more than twice as many patients were alive five years after getting it, plus the usual chemotherapy, than those given just the chemo — 13 percent versus 5 percent.

    "It's out of the box" in terms of how cancer is usually treated, and many doctors don't understand it or think it can help, said Dr. Roger Stupp, a brain tumor expert at Northwestern University in Chicago.

    Flash Mob Dancers Surprise Girl Battling Cancer

    [NATL] Flash Mob Dancers Surprise Girl Battling Cancer

    A flash mob surprised a 9-year-old Michigan girl battling cancer with a dance party. Over 300 people showed up to bring a smile to Tessa Prothero on her birthday.  

    (Published Tuesday, Feb. 28, 2017)

    He led the company-sponsored study while previously at University Hospital Zurich in Switzerland, and gave results Sunday at an American Association for Cancer Research meeting in Washington.

    "You cannot argue with them — they're great results," and unlikely to be due to a placebo effect, said one independent expert, Dr. Antonio Chiocca, neurosurgery chief at Brigham and Women's Hospital in Boston.

    Dr. George Demetri of the Dana-Farber Cancer Institute in Boston and a board member of the association hosting the conference, agreed but called the benefit modest, because most patients still die within five years. "It is such a horrible disease" that any progress is important, he added.

    ABOUT THE TREATMENT

    The device, called Optune, is made by Novocure, based in Jersey, an island near England. It's sold in the U.S., Germany, Switzerland and Japan for adults with an aggressive cancer called glioblastoma multiforme, and is used with chemo after surgery and radiation to try to keep these tumors from recurring, as most do.

    Patients cover their shaved scalp with strips of electrodes connected by wires to a small generator kept in a bag. They can wear a hat, go about their usual lives, and are supposed to use the device at least 18 hours a day. It's not an electric current or radiation, and they feel only mild heat.

    It supposedly works by creating low intensity, alternating electric fields that disrupt cell division — confusing the way chromosomes line up — which makes the cells die. Because cancer cells divide often, and normal cells in the adult brain do not, this in theory mostly harms the disease and not the patient.

    WHAT STUDIES SHOW

    In a 2011 study, the device didn't improve survival but caused fewer symptoms than chemo did for people whose tumors had worsened or recurred after standard treatments. The U.S. Food and Drug Administration approved it for that situation.

    A second study, in newly diagnosed patients, was stopped in 2014 after about half of the 695 participants had been tracked for at least 18 months, because those using the device were living several months longer on average than the rest.

    The FDA expanded approval but some doctors were leery because the device wasn't compared with a sham treatment — everyone knew who was getting what. Study leaders say a sham was impractical, because patients feel heat when they get the real thing, and many would refuse to shave their heads every few days and use an inconvenient device for years if the treatment might be fake.

    Some doctors said they would withhold judgment until there were long-term results on the whole group.

    Mom Tells Son's Story in Fight for NIH Funding

    [NATL-DC] Mom Tells Son's Story in Fight for NIH Funding

    Pediatric cancer research is one of the least funded and proposed budget cuts to NIH will deplete it even more. A family whose child died from pediatric cancer is testifying on Capitol Hill Wednesday, March 29, to save the funding. Tammi and Jason Carr in Michigan founded the ChadTough Foundation to honor their son Chad, who died at age 5 after battling a brain tumor. News4’s Shomari Stone reports. 

    (Published Tuesday, March 28, 2017)

    THE NEW RESULTS

    Now they're in: Median survival was 21 months for those given Optune plus chemo versus 16 months for those on chemo alone. Survival rates were 43 percent versus 31 percent at two years; 26 percent versus 16 percent at three years, and 13 percent versus 5 percent at five years.

    Side effects were minimal but included blood-count problems, weakness, fatigue and skin irritation from the electrodes.

    "The device is now impossible to ignore ... it absolutely is an advance," said Dr. Andrew Lassman, brain tumor chief at the Columbia University Medical Center/New York-Presbyterian Hospital. He consults for Novocure, as do some doctors running the study.

    The latest National Comprehensive Cancer Center guidelines include Optune as an appropriate treatment for brain tumors. It's also is being tested for pancreatic, ovarian and lung cancers; electrodes are worn on the belly or chest for those.

    THE PRICE

    Colon, Rectal Cancer on the Rise for Millennials

    [NATL] Colon, Rectal Cancer on the Rise for Millennials

    A new study by the American Cancer Society is showing a shocking increase in cancer among millennials. People in their 20s and 30s have double the risk of being diagnosed with colon cancer, as well as quadruple the risk for rectal cancer as their parents' generation did at the same age. 

    (Published Tuesday, Feb. 28, 2017)

    A big issue is cost — roughly $700 a day. Most U.S. insurers cover it but Medicare does not and "we are paying," said Novocure's chief executive, Bill Doyle. "We've never refused a patient regardless of insurance status."

    The price reflects "an extremely sophisticated medical device, made in very low quantities," with disposable parts changed several times a week and a support person for each patient, he said. Plus 17 years of lab, animal and human testing.

    That cost? "The round number is half a billion dollars," Doyle said.

    ONE PATIENT'S EXPERIENCE

    Joyce Endresen's insurance covers all but about $1,000 a year for her device. "It's a great plan, and that's why I still work," said Endresen, 52, employed by a direct mail company in suburban Chicago.

    She has scans every two months to check for cancer and "they've all been good," she said. "We celebrated two years of no tumor in December and went to South Africa."

    Doctors Remove 140-Pound Tumor from Pa. Woman

    [NATL-PHI] Doctors Remove 140-Pound Tumor from Schuylkill County Woman

    It was like a huge weight was lifted, and that's because it was. A Schuylkill County, Pennsylvania, woman lost 140 pounds when a surgeon removed a massive tumor from her body. NBC10's Randy Gyllenhaal spoke with her about her experience.

    (Published Friday, March 10, 2017)

    Doctors say many patients won't try the device because of the trouble involved or because they don't want a visible reminder of their cancer. Not Endresen.

    "I wear it and wear it proudly," she said. "It's an incredible machine and I'm fine not having hair."